Actinium Pharmaceuticals (NYSE:ATNM) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a report released on Tuesday,Benzinga reports. The firm currently has a $4.00 price objective on the stock.

Separately, Stephens restated an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Actinium Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $7.40.

Actinium Pharmaceuticals Trading Up 16.5 %

ATNM opened at $1.41 on Tuesday. The stock has a fifty day simple moving average of $1.20 and a two-hundred day simple moving average of $1.46. The company has a market cap of $43.99 million, a price-to-earnings ratio of -1.01 and a beta of 0.10. Actinium Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $10.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ATNM. Squarepoint Ops LLC increased its holdings in Actinium Pharmaceuticals by 25.4% in the 4th quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock worth $231,000 after buying an additional 37,159 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in Actinium Pharmaceuticals by 49.5% in the 4th quarter. Nuveen Asset Management LLC now owns 148,560 shares of the company’s stock worth $187,000 after buying an additional 49,214 shares in the last quarter. Deutsche Bank AG increased its holdings in Actinium Pharmaceuticals by 413.6% in the 4th quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock worth $155,000 after buying an additional 99,158 shares in the last quarter. Bank of America Corp DE increased its holdings in Actinium Pharmaceuticals by 76.6% in the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after buying an additional 34,176 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Actinium Pharmaceuticals by 4.9% in the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after buying an additional 11,812 shares in the last quarter. 27.50% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).